{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:52:39Z","timestamp":1790092359191,"version":"4.0.1"},"reference-count":34,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To compare all-cause and acute lymphoblastic leukemia (ALL)-related healthcare resource utilization (HCRU) and costs among patients receiving inotuzumab ozogamicin (InO) and blinatumomab (Blina) for ALL in the first relapsed\/refractory (R\/R) setting.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            We studied retrospective claims for adult commercial and Medicare Advantage enrollees with ALL receiving InO (n\u00a0=\u00a029) or Blina (n\u00a0=\u00a023) from 1\u00a0January 2015 to 16\u00a0February 2021. Mean per-patient-per-month (PPPM) HCRU and total costs were described and multivariable-adjusted PPPM total all-cause and ALL-related predicted costs were calculated.\n            <jats:bold>Results:<\/jats:bold>\n            Mean monthly ALL-related hospitalizations were the same for patients receiving InO and Blina (PPPM\u00a0=\u00a00.8 stays); however, the length of ALL-related hospital stay was almost twice as long among patients receiving Blina versus InO (ALL-related: InO\u00a0=\u00a07.6\u00a0days; Blina\u00a0=\u00a014.1\u00a0days; p\u00a0=\u00a00.346). In multivariable models, total ALL-related costs were 43% lower for InO compared with Blina (PPPM costs: InO\u00a0=\u00a0$93,767; Blina\u00a0=\u00a0$163,470; p\u00a0=\u00a00.021).\n            <jats:bold>Conclusion:<\/jats:bold>\n            In the first R\/R setting, patients who used InO had significantly lower all-cause and ALL-related costs compared with patients who used Blina, in part driven by hospitalization patterns.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0142","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T11:33:43Z","timestamp":1702640023000},"source":"Crossref","is-referenced-by-count":4,"title":["Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed\/refractory setting"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1445-8138","authenticated-orcid":false,"given":"Alexander","family":"Russell-Smith","sequence":"first","affiliation":[{"name":"Pfizer R&amp;D UK Ltd, Sandwich, Kent, CT13 9NJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3919-0721","authenticated-orcid":false,"given":"Louise","family":"Murphy","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN\u00a055344, USA"},{"name":"Author for correspondence: Tel.: ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN\u00a055344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cori","family":"Blauer-Peterson","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN\u00a055344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilou","family":"Terpenning","sequence":"additional","affiliation":[{"name":"Marilou Terpenning MD, LTD, Eagle, ID\u00a083616, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Cao","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN\u00a055344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN\u00a055344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4998-582X","authenticated-orcid":false,"given":"Tim","family":"Bancroft","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN\u00a055344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8379-2050","authenticated-orcid":false,"given":"Noah","family":"Webb","sequence":"additional","affiliation":[{"name":"Optum, Eden Prairie, MN\u00a055344, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1391-7794","authenticated-orcid":false,"given":"Stephanie","family":"Dorman","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Pfizer Inc, Kirkland QC, H9J 2M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3771-9283","authenticated-orcid":false,"given":"Richa","family":"Shah","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"6","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger T","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 7(6), e577 (2017).","journal-title":"Blood Cancer J."},{"issue":"1","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007","volume":"119","author":"Dores GM","year":"2012","unstructured":"Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007. Blood 119(1), 34\u201343 (2012).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel RL","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 72(1), 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"e_1_3_9_6_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia. Version 2.2022. (2023). www.nccn.org\/professionals\/physician_gls\/default.aspx#all"},{"issue":"1","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/stemcells.20-1-3","article-title":"Autologous stem cell transplantation in acute lymphocytic leukemia","volume":"20","author":"Gorin NC","year":"2022","unstructured":"Gorin NC. Autologous stem cell transplantation in acute lymphocytic leukemia. Stem Cells 20(1), 3\u201310 (2022).","journal-title":"Stem Cells"},{"issue":"12","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"Gokbuget N","year":"2016","unstructured":"Gokbuget N, Dombret H, Ribera JM International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica 101(12), 1524\u20131533 (2016).","journal-title":"Haematologica"},{"issue":"9","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376(9), 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian HM","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer 125(14), 2474\u20132487 (2019).","journal-title":"Cancer"},{"issue":"8","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375(8), 740\u2013753 (2016).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_9_12_2","unstructured":"BESPONSA (inotuzumab ozogamicin) for injection for intra venous use [full prescribing information]. Initial US Approval: 2017. Pfizer NY USA (2023). http:\/\/labeling.pfzer.com\/ShowLabeling.aspx?id=9503&format=PDF"},{"key":"e_1_3_9_13_2","unstructured":"Amgen. BLINCYTO\u00ae (blinatumomab) for injection for intra venous use [full prescribing information]. Initial US Approval: 2014. (2023). www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-om\/Blincyto\/blincyto_pi_hcp_english.pdf"},{"issue":"8","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s12325-019-00991-w","article-title":"Indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia","volume":"36","author":"Proskorovsky I","year":"2019","unstructured":"Proskorovsky I, Su Y, Fahrbach K Indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia. Adv. Ther. 36(8), 2147\u20132160 (2019).","journal-title":"Adv. Ther."},{"issue":"4","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s12325-019-0873-7","article-title":"Matching-adjusted indirect comparison of blinatumomab vs. inotuzumab ozogamicin for adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Song J","year":"2019","unstructured":"Song J, Ma Q, Gao W Matching-adjusted indirect comparison of blinatumomab vs. inotuzumab ozogamicin for adults with relapsed\/refractory acute lymphoblastic leukemia. Adv. Ther. 36(4), 950\u2013961 (2019).","journal-title":"Adv. Ther."},{"issue":"7","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/cncr.33340","article-title":"Sequencing of novel agents in relapsed\/refractory B-cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Badar T","year":"2021","unstructured":"Badar T, Szabo A, Dinner S Sequencing of novel agents in relapsed\/refractory B-cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed\/refractory acute lymphoblastic leukemia. Cancer 127(7), 1039\u20131048 (2021).","journal-title":"Cancer"},{"key":"e_1_3_9_17_2","doi-asserted-by":"crossref","unstructured":"Russell-Smith A Shah R Silverstein AR Characteristics healthcare utilization and costs associated with inotuzumab ozogamicin blinatumomab or other agents for the treatment of relapsed or refractory acute lymphoblastic leukemia. Presented at: European Hematology Association Congress. Vienna Austria 9\u201317 June 2022.","DOI":"10.1097\/01.HS9.0000849800.15938.16"},{"issue":"9","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/13696998.2017.1344127","article-title":"cost\u2013effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective","volume":"20","author":"Delea TE","year":"2017","unstructured":"Delea TE, Amdahl J, Boyko D cost\u2013effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. J. Med. Econ. 20(9), 911\u2013922 (2017).","journal-title":"J. Med. Econ."},{"key":"e_1_3_9_19_2","unstructured":"Compare Original Medicare & Medicare Advantage. Centers for Medicare and Medicaid Services. (2023). www.medicare.gov\/basics\/get-started-with-medicare\/get-more-coverage\/your-coverage-options\/compare-original-medicare-medicare-advantage"},{"key":"e_1_3_9_20_2","unstructured":"Optum. Addressing the need for real-world observational research solutions. (2023). www.optum.com\/content\/dam\/optum3\/optum\/en\/resources\/white-papers\/heor-observational-research-sol-wp.pdf"},{"issue":"8","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients","volume":"17","author":"Klabunde CN","year":"2007","unstructured":"Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann. Epidemiol. 17(8), 584\u2013590 (2007).","journal-title":"Ann. Epidemiol."},{"key":"e_1_3_9_22_2","unstructured":"National Cancer Institute (NCI). NCI Comorbidity Index Overview. (2023). https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html"},{"key":"e_1_3_9_23_2","unstructured":"US Department of Labor Bureau of Labor Statistics. Consumer Price Index. Medical Care. Series ID: CUUR0000SAM. US Department of Labor Bureau of Labor Statistics WA USA (2023). http:\/\/data.bls.gov\/cgi-bin\/surveymost?cu"},{"issue":"28","key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin PC","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34(28), 3661\u20133679 (2015).","journal-title":"Stat. Med."},{"key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/CEOR.S373316","article-title":"Costs by site of service for commercially-insured patients with metastatic pancreatic cancer receiving guideline-recommended chemotherapy: comparing community oncology and hospital outpatient settings","volume":"14","author":"Tomicki S","year":"2022","unstructured":"Tomicki S, Dieguez G, DeStephano D, Chang M, Cockrum P. Costs by site of service for commercially-insured patients with metastatic pancreatic cancer receiving guideline-recommended chemotherapy: comparing community oncology and hospital outpatient settings. Clinicoecon. Outcomes Res. 14, 653 (2022).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"4","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/jamaoncol.2017.5544","article-title":"Spending by commercial insurers on chemotherapy based on site of care, 2004\u20132014","volume":"4","author":"Winn AN","year":"2018","unstructured":"Winn AN, Keating NL, Trogdon JG, Basch EM, Dusetzina SB. Spending by commercial insurers on chemotherapy based on site of care, 2004\u20132014. JAMA Oncol. 4(4), 580\u2013581 (2018).","journal-title":"JAMA Oncol."},{"key":"e_1_3_9_27_2","unstructured":"Prescribing information. (2023). www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/blincyto\/blincyto_pi_hcp_english.pdf"},{"key":"e_1_3_9_28_2","unstructured":"Prescribing information. (2023). https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=9503&format=PDF"},{"issue":"26","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey DT","year":"2013","unstructured":"Teachey DT, Rheingold SR, Maude SL Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121(26), 5154\u20135157 (2013).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen A","year":"2018","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M Cytokine release syndrome. J. Immunother. Cancer 6(1), 56 (2018).","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40273-019-00812-6","article-title":"Cost effectiveness of blinatumomab versus inotuzumab ozogamicin in adult patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia in the United States","volume":"37","author":"Delea TE","year":"2019","unstructured":"Delea TE, Zhang X, Amdahl J Cost effectiveness of blinatumomab versus inotuzumab ozogamicin in adult patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia in the United States. Pharmacoeconomics 37(9), 1177\u20131193 (2019).","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11606-007-0130-7","article-title":"Can disease management target patients most likely to generate high costs? The impact of comorbidity","volume":"22","author":"Charlson M","year":"2007","unstructured":"Charlson M, Charlson RE, Briggs W, Hollenberg J. Can disease management target patients most likely to generate high costs? The impact of comorbidity. J. Gen. Intern. Med. 22(4), 464\u2013469 (2007).","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12916-017-0978-2","article-title":"The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases","volume":"15","author":"Cortaredona S","year":"2017","unstructured":"Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med. 15(1), 216 (2017).","journal-title":"BMC Med."},{"issue":"4","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jgo.2015.12.002","article-title":"Comorbidity in older adults with cancer","volume":"7","author":"Williams GR","year":"2016","unstructured":"Williams GR, Mackenzie A, Magnuson A Comorbidity in older adults with cancer. J. Geriatr. Oncol. 7(4), 249\u2013257 (2016).","journal-title":"J. Geriatr. Oncol."},{"issue":"8","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.7326\/0003-4819-138-8-200304150-00012","article-title":"Multivariable analysis: a primer for readers of medical research","volume":"138","author":"Katz MH","year":"2003","unstructured":"Katz MH. Multivariable analysis: a primer for readers of medical research. Ann. Intern. Med. 138(8), 644\u2013650 (2003).","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"100625","DOI":"10.1016\/j.eclinm.2020.100625","article-title":"cost\u2013effectiveness of cancer drugs: comparative analysis of the United States and England","volume":"29","author":"Cherla A","year":"2020","unstructured":"Cherla A, Renwick M, Jha A, Mossialos E. cost\u2013effectiveness of cancer drugs: comparative analysis of the United States and England. EClinicalMedicine 29\u201330, 100625 (2020).","journal-title":"EClinicalMedicine"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:39:19Z","timestamp":1706787559000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.57264\/cer-2023-0142"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0142","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"article-number":"e230142"}}